A groundbreaking study has revealed that the high degree of variation in antibody immunity between individual people is a primary force in determining which strains of the influenza virus will ultimately come to dominate a population. The research, published as a Reviewed Preprint in the journal eLife, suggests that the collective "immune landscape" of a community is far more complex than previously understood, and that this individual-level diversity creates the specific evolutionary pressures that allow certain flu variants to spread while others fade away.
The study, which utilized a sophisticated high-throughput sequencing-based assay to quantify antibody immunity, focused specifically on the H3N2 influenza subtype. By examining the immune responses of both children and adults, the research team provided what eLife editors have described as a compelling and important advancement in the field of population-level immunity. The findings are expected to have significant implications for immunologists, virologists, and the researchers responsible for developing the annual vaccines that protect millions of people worldwide.
Influenza is a notoriously elusive pathogen, characterized by its ability to undergo "antigenic drift." This process involves the steady accumulation of genetic mutations that alter the virus’s surface proteins, particularly hemagglutinin (HA). Because HA is the primary target for the antibodies generated by the human immune system following an infection or vaccination, even minor changes in its structure can allow the virus to evade detection. This constant state of flux explains why individuals can be reinfected with the flu multiple times throughout their lives and why global health organizations must update vaccine compositions every year to match the circulating strains.
However, the human immune response is not a uniform shield. It is a highly personalized defense system shaped by an individual’s unique "immunological biography"—the specific history of every flu strain they have ever encountered and every vaccine they have ever received. This history creates a phenomenon where two people standing in the same room may have vastly different levels of protection against the same flu variant.
“Differences in infection and vaccination histories within a group of people mean that population immunity to a specific variant of the flu is highly varied,” explained co-lead author Caroline Kikawa, an MD/PhD student at the University of Washington and the Fred Hutch Cancer Center. Kikawa noted that while scientists have long suspected that this variety influences the virus’s evolution, proving it has been an uphill battle. Conventional methods for measuring antibody levels are often slow and labor-intensive, capable of processing only a few samples at a time, which makes it nearly impossible to map the immunity of a broad population in real-time.
To overcome these technical hurdles, Kikawa and co-lead author Andrea Loes, a Staff Scientist at the Fred Hutch Cancer Center, worked under the direction of senior author Jesse Bloom to develop a new high-throughput neutralization assay. This tool allows researchers to simultaneously measure how effectively individual serum samples—the antibody-rich component of the blood—can block infection across a wide array of different flu viruses.
